ICIs leverage the patient’s own immune system to fight off tumor cells via the administration of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and PD-1 ligand (PD-L1). Here, PDCD1 is linked to neoplasm.